1. Home
  2. GH vs ADMA Comparison

GH vs ADMA Comparison

Compare GH & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$178.92

Market Cap

22.9B

Sector

Health Care

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$8.95

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
ADMA
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
2.0B
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
GH
ADMA
Price
$178.92
$8.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
4
Target Price
$119.79
$25.67
AVG Volume (30 Days)
1.7M
1.9M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
6.74
N/A
EPS
N/A
0.35
Revenue
$982,021,000.00
$42,219,783.00
Revenue This Year
$33.30
$27.46
Revenue Next Year
$28.27
$22.11
P/E Ratio
N/A
$25.57
Revenue Growth
32.88
43.85
52 Week Low
$55.38
$7.21
52 Week High
$183.51
$20.46

Technical Indicators

Market Signals
Indicator
GH
ADMA
Relative Strength Index (RSI) 62.09 41.65
Support Level $153.88 $8.20
Resistance Level N/A $8.97
Average True Range (ATR) 8.48 0.27
MACD 1.69 -0.09
Stochastic Oscillator 83.84 32.88

Price Performance

Historical Comparison
GH
ADMA

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: